<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00510614</url>
  </required_header>
  <id_info>
    <org_study_id>PRO07030019</org_study_id>
    <nct_id>NCT00510614</nct_id>
  </id_info>
  <brief_title>Tinidazole for Recurrent Bacterial Vaginosis: A Pilot Study</brief_title>
  <official_title>Tinidazole for Recurrent Bacterial Vaginosis: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mission Pharmacal</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is being done to evaluate the use of an oral (by mouth) medication called&#xD;
      tinidazole to initially treat BV and then to see if additional treatment with tinidazole&#xD;
      keeps women from getting this infection back within 3 months. Tinidazole is currently&#xD;
      approved by the United States Food and Drug Administration (FDA) to treat bacterial vaginosis&#xD;
      (BV).&#xD;
&#xD;
      This study will evaluate the use of tinidazole to treat a woman's current BV infection and&#xD;
      then will look at using tinidazole as a suppressive treatment (taking medication regularly to&#xD;
      attempt to decrease the &quot;bad&quot; bacteria from growing back). The suppressive treatment phase&#xD;
      will include using tinidazole twice a week compared to using placebo twice a week and then&#xD;
      following women for recurrence of BV. The purpose of this study is to determine if tinidazole&#xD;
      suppression will prevent BV from coming back within 3 months of treatment.&#xD;
&#xD;
      The investigators hypothesize that women with a history of recurrent bacterial vaginosis who&#xD;
      are randomized to a suppressive regimen (a dose of medication given on a regular basis to&#xD;
      attempt to control the bacteria that causes bacterial vaginosis) of tinidazole will have&#xD;
      lower recurrence rates and a longer time to recurrence of bacterial vaginosis when compared&#xD;
      to those women randomized to placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Differences in the proportion of women clinically cured at each visit between the two therapy arms will be evaluated using Fisher's-exact test.</measure>
    <time_frame>at each study visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier product-limit estimation will be used to obtain estimates of the median time to BV recurrence.</measure>
    <time_frame>at each study visit</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Bacterial Vaginosis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 gram tinidazole twice weekly for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo twice weekly for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tinidazole</intervention_name>
    <description>1 gram twice weekly for 12 weeks</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Tindamax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>one pill twice weekly for 12 weeks</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-45 at time of enrollment.&#xD;
&#xD;
          2. Recurrent BV as defined by:&#xD;
&#xD;
               -  2 previously documented diagnoses of BV in the past 6 months or&#xD;
&#xD;
               -  3 previously documented diagnoses of BV in the past year&#xD;
&#xD;
          3. Non-pregnant, non-lactating.&#xD;
&#xD;
          4. Premenopausal.&#xD;
&#xD;
          5. Presence of bacterial vaginosis at the enrollment visit using Amsel Criteria (at least&#xD;
             3 of 4):&#xD;
&#xD;
               -  Presence of homogenous vaginal discharge&#xD;
&#xD;
               -  pH of vaginal secretions of &gt; 4.7&#xD;
&#xD;
               -  Presence of a positive &quot;whiff&quot; test of the vaginal secretions upon mixing with&#xD;
                  10% KOH&#xD;
&#xD;
               -  Presence of &gt; 20% clue cells on saline microscopy&#xD;
&#xD;
          6. Willingness to undergo randomization to a possible placebo arm (for suppressive&#xD;
             therapy).&#xD;
&#xD;
          7. Ability to undergo informed consent.&#xD;
&#xD;
          8. Willingness to refrain from use of any intravaginal products (including douching,&#xD;
             contraceptive spermicides, creams, gels, foams).&#xD;
&#xD;
          9. Currently using an acceptable method of birth control (such as a hormonal method&#xD;
             including oral contraceptives, Depo Provera, Ortho Evra, abstinence x 60 days,&#xD;
             consistent condom use, surgically sterile, lesbian orientation).&#xD;
&#xD;
         10. Willing to refrain from alcohol consumption during use of study medication and three&#xD;
             days following completion of medication (which includes the 10 day open label&#xD;
             treatment and the entire 3 month suppressive phase of treatment).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known active sexually transmitted infection at the time of enrollment with C.&#xD;
             trachomatis, N. gonorrhoeae, T. vaginalis, or active (symptomatic) vulvovaginal&#xD;
             candidiasis.&#xD;
&#xD;
          2. Current use of anticoagulants/blood thinners (i.e. warfarin, coumadin, heparin).&#xD;
&#xD;
          3. Current use of any of the following medications: lithium, fluorouracil,&#xD;
             anticonvulsant/seizure medications, Questran (cholestyramine) or CYP3A4&#xD;
             inducer/inhibitors (i.e. phenobarbital, rifampin, phenytoin, fosphenytoin).&#xD;
&#xD;
          4. Use of Antabuse (disulfiram) currently or within the past 2 weeks.&#xD;
&#xD;
          5. Allergy to metronidazole or tinidazole (related drugs with likely cross-over allergy&#xD;
             potential).&#xD;
&#xD;
          6. Use of any antibiotics (oral or vaginal) in the past 7 days.&#xD;
&#xD;
          7. Current use of an IUD, Nuva Ring.&#xD;
&#xD;
          8. Known immunosuppressive condition (i.e. HIV, end-stage renal disease,&#xD;
             currently-treated diabetes mellitus, etc.) or on immunosuppressive medications [i.e.&#xD;
             steroids, cyclosporine, Protopic (tacrolimus), immunomodulators].&#xD;
&#xD;
          9. Participation in an investigational drug study within the past 30 days.&#xD;
&#xD;
         10. Any condition which in the opinion of the investigator would impose a health risk to&#xD;
             the subject or interfere with the evaluation of the study medication or procedures.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Beigi, MD, MSc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Magee-Womens Hospital of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <study_first_submitted>August 1, 2007</study_first_submitted>
  <study_first_submitted_qc>August 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2007</study_first_posted>
  <last_update_submitted>February 16, 2011</last_update_submitted>
  <last_update_submitted_qc>February 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2011</last_update_posted>
  <responsible_party>
    <name_title>Richard H Beigi, MD</name_title>
    <organization>University of Pittsburgh</organization>
  </responsible_party>
  <keyword>Bacterial Vaginosis</keyword>
  <keyword>Recurrent Bacterial Vaginosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginosis, Bacterial</mesh_term>
    <mesh_term>Vaginal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinidazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

